Form 4: Arcellx CFO Michelle Gilson Exercises Stock Options
Statement of Changes in Beneficial Ownership
Arcellx CFO Michelle Gilson exercised options to acquire 38,110 shares of common stock on April 15 and 16, 2026.
Summary
- Michelle Gilson, Chief Financial Officer of Arcellx, Inc., exercised stock options for a total of 38,110 shares of common stock.
- The transactions occurred on April 15, 2026 (36,000 shares) and April 16, 2026 (2,110 shares).
- The exercise price for all shares was $8.66 per share.
- Following these transactions, the reporting person holds 67,048 shares directly and 5,000 shares indirectly through a family charitable foundation.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, representing standard executive compensation activity rather than a strategic shift or market-moving event.
Positives
- Insider confidence is demonstrated through the exercise of vested stock options by the CFO.
- The reporting person maintains a significant direct and indirect equity stake in the company.
Negatives
- None identified; this is a routine disclosure of equity compensation exercise.
Risks
- The reporting person's continued service is required for the vesting of remaining unexercised options.
Future Outlook
The filing does not provide forward-looking financial guidance, as it is a standard disclosure of insider equity transactions.
Industry Context
StockSavvy.ai notes that routine option exercises by C-suite executives in the biotechnology sector are standard components of executive compensation packages and generally do not signal a change in corporate strategy or outlook.
Comparison to Industry Standards
- The exercise of options at a set strike price is consistent with standard equity incentive plans (2022 Plan) common among publicly traded biotech firms.
- The reporting structure follows standard SEC Section 16(a) compliance requirements.
Related Party Transactions
- The reporting person serves as the President of a family charitable foundation that holds 5,000 shares of Arcellx common stock.
Stakeholder Impact
- Minimal impact on shareholders as this reflects the exercise of existing compensation rather than a new market transaction.
Next Steps
- Continued monitoring of future Form 4 filings for potential sales or further acquisitions by insiders.
Key Dates
| Date | Description |
|---|---|
| 05/23/2022 | Vesting Commencement Date for the exercised stock options. |
| 04/15/2026 | Date of first transaction involving 36,000 shares. |
| 04/16/2026 | Date of second transaction involving 2,110 shares. |
| 04/17/2026 | Date of filing signature. |
| 05/23/2032 | Expiration date of the stock options. |
Keywords
Arcellx, ACLX, Insider Trading, Form 4, Stock Options, CFO, Biotech
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.